Redeye returns with an update on Saniona. We are impressed by the company’s deal-making capabilities...
The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserv...
Redeye leaves Addnode’s CMD with a positive impression, as the company’s ambition for growth and mar...
Redeye comments on today’s news from Cheffelo, where financial targets have been raised ahead of its...
Redeye provides an update following the company’s Q2 report, which demonstrated significant sequenti...
Yesterday evening, it was announced that Ascelia had raised around SEK30m in a directed share issue ...
Redeye believes the data is solid and in line with previous readouts.
Redeye updates its valuation of Verve, which within two days announced two acquisitions that complem...
After announcing the proposed rights issue, we update our Base Case, including the number of shares.
Redeye comments on the directed share issue in which Sivers Semiconductors raised SEK95m before tran...
Atria announced today its TOGETHER 2030 strategy for 2025-30 with refined financial targets.
Q-linea proposes that a SEK 322m rights issue be secured at 85.
Första halvåret visade högre intäkter än föregående år, och tidiga beställningar inför tredje kvarta...
Redeye is positive on Senzime’s recent news flow, with contracts from important US hospitals.
Redeye comments on Verve's announced acquisition. The company is acquiring Acardo Group for EUR24.
With the rapidly occurring energy transition, significant investments have been made in the grid and...
Redeye is not surprised by the high subscription rate, considering the share has traded above the st...
Redeye comments on the announcement that CEO Pål Ryfors will step down of his own volition, with cur...
Redeye is pleased with TO13’s preliminary subscription rate of 91%.
Redeye is surprised by the low 69% acceptance rate from Integrum’s shareholders on the SEK44 bid by ...
